Cargando…

Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells

BACKGROUND: Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia, as well as enhancing anti-cancer efficacy. We i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ariaans, Gerke, Jalving, Mathilde, Vries, Emma Geertruida Elisabeth de, Jong, Steven de
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372253/ https://www.ncbi.nlm.nih.gov/pubmed/28356082 http://dx.doi.org/10.1186/s12885-017-3230-8

Ejemplares similares

Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells
por: Wang, Yunshan, et al.
Publicado: (2015)

Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment
por: Vitali, Eleonora, et al.
Publicado: (2020)

Type 2 Diabetes Mellitus and Clinicopathological Tumor Characteristics in Women Diagnosed with Breast Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Fan, et al.
Publicado: (2021)

A phase Ib study of everolimus combined with metformin for patients with advanced cancer
por: Molenaar, Remco J., et al.
Publicado: (2017)

(18)F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions
por: Hendriks, Anne M., et al.
Publicado: (2021)

Metformin Potentiates the Anticancer Effect of Everolimus on Cervical Cancer In Vitro and In Vivo
por: Chen, Ya-Hui, et al.
Publicado: (2021)

Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma
por: Hong, Seong-Hwi, et al.
Publicado: (2022)

Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative (18)F-FDG PET/CT analysis
por: de Heer, Ellen C., et al.
Publicado: (2018)

Glucose promotes breast cancer aggression and reduces metformin efficacy
por: Wahdan-Alaswad, Reema, et al.
Publicado: (2013)

Everolimus in the Treatment of Metastatic Breast Cancer
por: Royce, Melanie E, et al.
Publicado: (2015)

Pyruvate Dehydrogenase Kinase Inhibition by Dichloroacetate in Melanoma Cells Unveils Metabolic Vulnerabilities
por: Tiersma, Jiske F., et al.
Publicado: (2022)

The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
por: de Haan-Du, Jing, et al.
Publicado: (2023)

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2019)

Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer
por: Wahdan-Alaswad, RS, et al.
Publicado: (2018)

Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus
por: Souza, Matheus Leite Ramos de, et al.
Publicado: (2019)

High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells
por: Varghese, Sharon, et al.
Publicado: (2019)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts
por: Mercatali, Laura, et al.
Publicado: (2016)

Use of Metformin and Survival of Diabetic Women with Breast Cancer
por: Peeters, Paul J.H.L., et al.
Publicado: (2013)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders
por: Krueger, Darcy A., et al.
Publicado: (2017)

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study
por: Pizzuti, Laura, et al.
Publicado: (2017)

Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer
por: Lousberg, Laurence, et al.
Publicado: (2017)

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
por: Yi, Zongbi, et al.
Publicado: (2017)

Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer
por: Kimura, Mariko, et al.
Publicado: (2018)

Immunological effects of everolimus in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2017)

Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer
por: Guo, Hui, et al.
Publicado: (2016)

The Anti-Breast Cancer Effect and Mechanism of Glimepiride-Metformin Adduct
por: Long, Liangyuan, et al.
Publicado: (2020)

The Anti-Diabetic Drug Metformin from the Neuropathy Perspective
por: Won, Jong Chul
Publicado: (2020)

Inhibition of androgen receptor enhanced the anticancer effects of everolimus through targeting glucose transporter 12
por: Cao, Bo, et al.
Publicado: (2023)

Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
por: Kuik, Kelvin Teck-Hong, et al.
Publicado: (2014)

Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers
por: Bihani, Teeru, et al.
Publicado: (2014)

Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells
por: Simone, Valeria, et al.
Publicado: (2015)

Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer
por: Browne, Andrew J., et al.
Publicado: (2017)

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer
por: Pascual, Tomas, et al.
Publicado: (2017)

Everolimus-associated Acute Kidney Injury in Patients with Metastatic Breast Cancer
por: Chandra, A., et al.
Publicado: (2017)

[Retracted] Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells
por: Taglieri, Ludovica, et al.
Publicado: (2023)

Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report
por: Ballatore, Z., et al.
Publicado: (2016)

Selective cytotoxicity of the anti-diabetic drug, metformin, in glucose-deprived chicken DT40 cells
por: Kadoda, Kei, et al.
Publicado: (2017)

Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells
por: Alhourani, Abdelnour H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jpikai11pb7btkcid8ockfov4i